文献速递痛风与晶体性关节病

慢性难治性痛风伴与不伴临床可见痛风石患者的特征及对培戈洛酶的反应

Characterization of patients with chronic refractory gout who do and do not have clinically apparent tophi and their response to pegloticase.
PubMed 文献 · Rheumatology (Oxford) · 2019-03-06

基于两项培戈洛酶随机对照试验,比较慢性难治性痛风伴临床可见痛风石与无痛风石患者的基线与治疗差异。伴痛风石者年龄更大、病程更长、关节计数与患者整体评估更差、生活质量更低、估算肾小球滤过率更低。两组培戈洛酶治疗均获临床获益,但肾功能未见改变。

要点

  • 伴临床可见痛风石者疾病更重且肾功能更差,应加强评估。
  • 培戈洛酶改善两组血清尿酸与痛风发作,但无痛风石者部分患者报告结局未改善。
  • 培戈洛酶降低尿尿酸/肌酐比值但未改变估算肾小球滤过率。

核心结论

  • 慢性难治性痛风伴临床可见痛风石者疾病更严重且肾功能更低,两组培戈洛酶治疗均有显著临床获益但肾功能无变化。

研究设计与样本

  • 基于两项培戈洛酶随机对照试验,纳入慢性难治性痛风伴或不伴临床可见痛风石患者,比较基线及治疗期间组间差异。

主要发现

  • 伴痛风石者年龄显著更大、病程显著更长、压痛与肿胀关节数更多、患者整体评估与HAQ-DI评分更高、Arthritis-Specific Health Index评分更低。
  • 伴痛风石者SF-36生理功能、生理角色、社会功能及生理健康总评分显著更低,平均估算肾小球滤过率显著更低。
  • 培戈洛酶使伴痛风石者血清尿酸、痛风发作、患者整体评估、压痛关节、肿胀关节、HAQ-DI、疼痛视觉模拟评分及SF-36躯体疼痛显著改善。
  • 无痛风石者血清尿酸、痛风发作、患者整体评估、压痛关节及SF-36躯体疼痛显著改善,但肿胀关节、HAQ-DI功能评分及疼痛视觉模拟评分未显著改善。
  • 培戈洛酶显著降低尿尿酸/肌酐比值,但对估算肾小球滤过率无影响。

临床怎么用

  • 对慢性难治性痛风伴临床可见痛风石者应关注更重的关节症状、更差的生活质量与更低肾功能,培戈洛酶可改善临床结局但不应期待肾功能改善。

局限性

  • 原文未报告具体样本量、效应值、置信区间与P值,且为两项随机对照试验的事后比较分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To determine the characteristics and response to pegloticase of patients with chronic refractory gout with and without clinically apparent tophi. METHODS: Results from two randomized controlled trials of pegloticase in patients with chronic refractory gout with clinically apparent tophi or without tophi were used to assess baseline and on-treatment between-group differences. RESULTS: Patients with tophi were significantly older than those without tophi, had a significantly longer duration of disease, higher numbers of tender and swollen joints, higher Patient Global Assessment scores and Health Assessment Questionnaire-Disability Index scores, and lower Arthritis-Specific Health Index scores. Patients with tophaceous gout also had significantly lower scores for physical functioning, role physical, social functioning, and the physical component summary scores of the Short Form 36 vs patients without tophi. In addition, subjects with clinically apparent tophi had a significantly lower mean estimated glomerular filtration rate. Pegloticase treatment of tophaceous patients caused significant reductions in serum urate, flares, Patient Global Assessment, tender joints, swollen joints, Health Assessment Questionnaire-Disability Index, visual analogue scale pain and Short Form 36 Bodily Pain, whereas patients without tophi had significant improvement in serum urate, flares, Patient Global Assessment, tender joints, and Short Form 36 Bodily Pain, but not swollen joints, Health Assessment Questionnaire-Disability Index functional score or pain visual analogue scale. Treatment with pegloticase had no effect on estimated glomerular filtration rate despite significant lowering of the urinary uric acid: creatinine ratio. CONCLUSION: Patients with chronic refractory gout and clinically apparent tophi have more severe disease as well as reduced renal function. Both groups experienced significant clinical benefit with pegloticase treatment, although no change in renal function was noted.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Lawrence Edwards N, Singh JA, Troum O, et al. Characterization of patients with chronic refractory gout who do and do not have clinically apparent tophi and their response to pegloticase. Rheumatology (Oxford). 2019. PMID: 30843588. doi:10.1093/rheumatology/kez017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。